dpp 4 inhibitors vs glp 1 Differences between GLP-1 receptor agonists and DPP-4 Use of DPP-4 inhibitors and

Breast cancer and colorectal cancer studies have shown that epithalon exhibits strong anti-tumor effects and inhibits the expression of carcinogenic receptors [6]

10.3389/fnmol.2017.00377 142

The disruption of this endothelial-pericyte metabolic coupling restricts microvascular perfusion, intensifies vasogenic edema, facilitates leukocyte infiltration, and progressively worsens parenchymal mitochondrial stress [17, 18]

This is not an independently verified or audited statistic

Of more than 350 patients he has treated with this microdosing approach, 60%90% have responded with decreases in fatigue, brain fog, pain, and symptoms of mast cell activation syndrome (MCAS), an inflammatory condition common in people with long COVID, Kaufman said

The safety of GLP-1 receptor agonists during breastfeeding has not been well-studied